Home Newsfeeds Oppenheimer Maintains Outperform on Prometheus Biosciences, Raises Price Target to $125

Oppenheimer Maintains Outperform on Prometheus Biosciences, Raises Price Target to $125

Oppenheimer analyst Jeff Jones maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $61 to $125.

byBenzinga Newsdesk

December 8, 2022

1 minute read

Oppenheimer analyst Jeff Jones maintains Prometheus Biosciences (NASDAQ:RXDX) with a Outperform and raises the price target from $61 to $125.

What Happened With Plug Power Stock During Tuesday’s Session

By Henry Khederian

June 6, 5:46 PM

Plug Power Inc (NASDAQ: PLUG) shares closed higher by 7.36% to $9.04 Tuesday, despite a lack of company-specific news.

PLUG

News

Wisekey International Holding’s Security Chips Are Protecting IoT Devices Connecting Smart Cities

By Benzinga Newsdesk

February 8, 3:40 AM

WISeKey International Holding (("WISeKey", SIX: WIHN, NASDAQ:WKEY), a leading cybersecurity, AI and IoT company, announced today that its security chips are being used to protect all sort of IoT

WKEY

Agra Ventures Announces Details Of Share Consolidation, Name Change And Ticker Symbol Change

By Vuk Zdinjak

August 2, 10:25 AM

Agra Ventures Ltd. (OTCPK:AGFAF) (CSE:AGRA) will be proceeding with the consolidation of its issued and outstanding share capital, changing its name to “Digicann Ventures Inc.” and changing its stock ticker symbol on the Canadian Securities Exchange to “DCNN”.

AGFAF